Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...